Industry Insight
Discovery Technology
Analytical Laboratory Technology
Biopharma
Manufacturing
Delivery Systems
Ingredients, Formulation and Finishing
Bioprocessing
View our other publications with free access to extensive archives
  To print this article:
Existing subscribers please log in:
 
  USER NAME  
  PASSWORD  
   Or select

Or become a subscriber
 
 
 

The Emergence of Antibody Fragments and Derivatives

Antibody fragments have distinct advantages over antibodies, and with both commercially viable fragments in the marketplace and numerous candidates in various stages of development, they look set to offer a credible therapeutic alternative to full-length mAbs.

By Gurdeep Singh Athwal at Novozymes BioPharma UK (July 2009)

Keywords: antibody fragments, Kohler, Milstein, monoclonal, mAbs, technologies, production, development, growth

    View full article    |    Back to Biopharma section




Advair,Flovent,VentolinSymbicort,Serevent,FlonaseAstelin Rhinocort
IPTonline © 2004 The Pharmaceutical Technology Journal | Terms and Conditions | info@iptonline.com | UK Contacts |
Providing a platform of communication on new ideas, developments and innovations | UK Tel No. +44 20 77243456 | Back to top of page |